The third quarter was a rough one for most investors, as fears of an interest rate hike in the U.S, a weakening economy in China, and a stagnant Europe, weighed heavily on the minds of investors. Both the S&P 500 and …
INSIDER MONKEY · 11/28/2015
Protalix BioTherapeutics Inc
Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 1.09 on Friday. The stock’s 50 day moving average is $1.05 and its 200 day moving average is $1.56. Protalix BioTherapeutics has a 52-week low of $0.95 …
Watch List News · 11/27/2015
Protalix BioTherapeutics
PLx Pharma Inc. (Nasdaq: PLXP) filed an amended registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $80.5 million, which compares with the original expectation of …
StreetInsider · 11/19/2015
More from Bing News
Protalix BioTherapeutics (NYSE:PLX) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst …
Ticker Report · 11/26/2015
Protalix BioTherapeutics
Shares of Protalix BioTherapeutics (NYSE:PLX) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the … · 1 day ago
Protalix BioTherapeutics
The stock has a market cap of $35.46 billion and a P/E ratio of ... The enterprise storage segment consists of LSI Corporation’s (LSI’s) storage products and PLX Technology, Inc.’s (PLX’s) peripheral component … · 12 hours ago
Avago Technologies
The stock has a consensus rating of “Hold” and an average price ... Orenitram Combination Therapy, Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb, for the treatment of High-risk neuroblastoma; Ex-Vivo ... · 11/23/2015
United Therapeutics
Protalix BioTherapeutics, Inc. (PLX - Snapshot Report) was a big mover last session, as its shares rose almost 9% on the day. The upside was driven by the news of Pfizer (PFE - Analyst Report) building its position in Protalix. This also led to far more ...
ZACKS · 10/26/2015
One stock that might be an intriguing choice for investors right now is Protalix BioTherapeutics, Inc. (PLX). This is because this security in the Biotechnology space is seeing solid earnings estimate revision activity, and is in great company from a Zacks ...
Yahoo Finance · 4/2/2015
Pfizer recently acquired its position in Protalix for $10 million as part of a collaboration deal between the companies PLX stock finally closed at $1.12, up $0.09 (or +8.74%) from the previous day’s closing, with a total volume of 659,256 shares traded ...
Galaxy Stocks · 10/24/2015